Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FULC NASDAQ:LXEO NASDAQ:RANI NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$7.25+4.2%$7.52$5.51▼$15.74$463.77M3.02764,149 shs535,613 shsLXEOLexeo Therapeutics$5.76+1.1%$6.17$2.43▼$10.99$447.57M1.52683,720 shs1.24 million shsRANIRani Therapeutics$1.05-4.5%$1.02$0.39▼$3.87$136.06M0.74772,440 shs891,515 shsZURAZura Bio$4.80+1.1%$5.77$0.98▼$7.44$450.68M0.09695,994 shs321,810 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics+4.17%+1.97%-6.21%-33.24%+25.22%LXEOLexeo Therapeutics+1.05%-7.54%-9.72%-12.33%+103.53%RANIRani Therapeutics-4.55%+9.36%+35.03%-16.00%+117.98%ZURAZura Bio+1.05%-1.56%-15.49%-22.71%+296.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$7.25+4.2%$7.52$5.51▼$15.74$463.77M3.02764,149 shs535,613 shsLXEOLexeo Therapeutics$5.76+1.1%$6.17$2.43▼$10.99$447.57M1.52683,720 shs1.24 million shsRANIRani Therapeutics$1.05-4.5%$1.02$0.39▼$3.87$136.06M0.74772,440 shs891,515 shsZURAZura Bio$4.80+1.1%$5.77$0.98▼$7.44$450.68M0.09695,994 shs321,810 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics+4.17%+1.97%-6.21%-33.24%+25.22%LXEOLexeo Therapeutics+1.05%-7.54%-9.72%-12.33%+103.53%RANIRani Therapeutics-4.55%+9.36%+35.03%-16.00%+117.98%ZURAZura Bio+1.05%-1.56%-15.49%-22.71%+296.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFULCFulcrum Therapeutics 2.50Moderate Buy$19.00162.07% UpsideLXEOLexeo Therapeutics 2.89Moderate Buy$18.88227.69% UpsideRANIRani Therapeutics 2.67Moderate Buy$7.80642.86% UpsideZURAZura Bio 2.67Moderate Buy$10.75123.96% UpsideCurrent Analyst Ratings BreakdownLatest RANI, FULC, LXEO, and ZURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026LXEOLexeo Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/1/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026FULCFulcrum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026RANIRani Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.004/8/2026ZURAZura Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/1/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $5.003/27/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026RANIRani Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.003/23/2026ZURAZura Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.003/20/2026ZURAZura Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $15.00(Data available from 5/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFULCFulcrum Therapeutics$80M6.04N/AN/A$5.00 per share1.45LXEOLexeo TherapeuticsN/AN/AN/AN/A$2.95 per shareN/ARANIRani Therapeutics$1.63M79.68N/AN/A$0.34 per share3.09ZURAZura BioN/AN/AN/AN/A$2.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%N/ALXEOLexeo Therapeutics-$99.96M-$2.19N/AN/AN/AN/A-47.48%-41.72%N/ARANIRani Therapeutics-$29.67M-$0.59N/AN/AN/AN/A-774.04%-106.02%5/13/2026 (Estimated)ZURAZura Bio-$99.35M-$1.09N/AN/AN/AN/A-55.74%-48.07%N/ALatest RANI, FULC, LXEO, and ZURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026RANIRani Therapeutics-$0.06N/AN/AN/A$1.13 millionN/A5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/7/2026Q1 2026ZURAZura Bio-$0.17-$0.22-$0.05-$0.22N/AN/A4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 million3/16/2026Q4 2025ZURAZura Bio-$0.18-$0.49-$0.31-$0.49N/AN/A2/24/2026Q4 2025FULCFulcrum Therapeutics-$0.31-$0.31N/A-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFULCFulcrum TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFULCFulcrum TherapeuticsN/A34.3334.33LXEOLexeo TherapeuticsN/A14.1611.21RANIRani TherapeuticsN/A4.214.21ZURAZura BioN/A19.339.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFULCFulcrum Therapeutics89.83%LXEOLexeo Therapeutics60.67%RANIRani Therapeutics30.19%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipFULCFulcrum Therapeutics7.00%LXEOLexeo Therapeutics5.30%RANIRani Therapeutics26.51%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFULCFulcrum Therapeutics10066.63 million61.97 millionOptionableLXEOLexeo Therapeutics5878.52 million74.36 millionNot OptionableRANIRani Therapeutics110123.69 million90.90 millionOptionableZURAZura Bio394.88 million81.38 millionOptionableRANI, FULC, LXEO, and ZURA HeadlinesRecent News About These CompaniesAnalysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)May 11 at 9:56 PM | theglobeandmail.comZura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 9, 2026 | marketbeat.comZura Bio (NASDAQ:ZURA) Releases Earnings Results, Misses Estimates By $0.05 EPSMay 7, 2026 | marketbeat.comZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | businesswire.comZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | businesswire.comZura Bio (ZURA) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comZura Bio Limited Class AApril 24, 2026 | edition.cnn.comOne Zura Bio Insider Raised Their Stake In The Previous YearApril 23, 2026 | finance.yahoo.comZura Bio (NASDAQ:ZURA) Shares Down 5.3% - Time to Sell?April 20, 2026 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA)April 16, 2026 | theglobeandmail.comZura Bio: Momentum Is Real, But TibuSHIELD Needs To DeliverMarch 31, 2026 | seekingalpha.comZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 19, 2026 | businesswire.comZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressMarch 5, 2026 | businesswire.comInsider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Acquires 2,000,000 Shares of StockMarch 3, 2026 | insidertrades.comZura Bio to Participate in Upcoming Investor ConferencesMarch 2, 2026 | businesswire.comZura Bio Raises $144 Million To Advance Autoimmune Drug PipelineFebruary 27, 2026 | ventureburn.comVZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesFebruary 27, 2026 | businesswire.comZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 25, 2026 | businesswire.comZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 24, 2026 | finance.yahoo.comZura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.February 23, 2026 | businesswire.comZura Bio Advances Tibulizumab Strategy in Autoimmune DiseasesFebruary 12, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 20263 Overlooked Nuclear Fuel Supply Chain WinnersBy Nathan Reiff | April 26, 2026Atomic Dividends: Big Tech's New Energy BetBy Jeffrey Neal Johnson | May 5, 2026RANI, FULC, LXEO, and ZURA Company DescriptionsFulcrum Therapeutics NASDAQ:FULC$7.25 +0.29 (+4.17%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$7.26 +0.01 (+0.19%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Lexeo Therapeutics NASDAQ:LXEO$5.76 +0.06 (+1.05%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$5.76 0.00 (0.00%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Rani Therapeutics NASDAQ:RANI$1.05 -0.05 (-4.55%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$1.06 +0.01 (+1.14%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Zura Bio NASDAQ:ZURA$4.80 +0.05 (+1.05%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$5.00 +0.20 (+4.17%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
